Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. May 27, 2022; 14(5): 984-991
Published online May 27, 2022. doi: 10.4254/wjh.v14.i5.984
Published online May 27, 2022. doi: 10.4254/wjh.v14.i5.984
Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database
Amaninder Dhaliwal, Department of Gastroenterology and Hepatology, Moffitt Cancer Center, Tampa, FL 33612, United States
Banreet Dhindsa, Department of Gastroenterology and Hepatology, University of Nebraska Medical Center, Omaha, NE 68198, United States
Daryl Ramai, Department of Internal Medicine, The Brooklyn Hospital Center, Brooklyn, NY 11201, United States
Harlan Sayles, Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE 68198, United States
Saurabh Chandan, Rajani Rangray, Department of Gastroenterology and Hepatology, Creighton University Medical Center, Omaha, NE 68124, United States
Author contributions: Dhaliwal A analysis and interpretation of data, drafting the article; Dhindsa B drafting the article; Ramai D acquisition of data; Sayles H analysis and interpretation of data; Chandan S critical revision; Rangray R critical revision, final approval.
Institutional review board statement: No IRB approval needed as this is a database study.
Conflict-of-interest statement: The authors deny any conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Amaninder Dhaliwal, MD, Academic Fellow, Department of Gastroenterology and Hepatology, Moffitt Cancer Center, 12902 USF Magnolia Drive, FOB 2 GI Program, Tampa, FL 33612, United States. dramaninderdhaliwal@gmail.com
Received: April 4, 2021
Peer-review started: April 4, 2021
First decision: July 6, 2021
Revised: August 6, 2021
Accepted: April 9, 2022
Article in press: April 9, 2022
Published online: May 27, 2022
Processing time: 414 Days and 16.3 Hours
Peer-review started: April 4, 2021
First decision: July 6, 2021
Revised: August 6, 2021
Accepted: April 9, 2022
Article in press: April 9, 2022
Published online: May 27, 2022
Processing time: 414 Days and 16.3 Hours
Core Tip
Core Tip: Due to the limited availability of donor organs and high mortality rate on the transplant waiting list, newer strategies are needed. Use of direct acting anti-viral agents have led to high success rates for hepatitis C virus (HCV) treatment. Our study shows, the survival rates in hepatitis C positive donors and negative recipients are similar as compared to both hepatitis C negative donors and recipients. This study supports the use of hepatitis C positive organs in the selected group of recipients with and without HCV infection.